Login to Your Account



‘Quanticel’ the Company Later?

Pharmakea Inks Celgene Deal: $35M for Cancer and Fibrotic Push

By Randy Osborne
Staff Writer

Friday, October 4, 2013
Celgene Corp. put still more chips on the biotech table, entering a confirmed $35 million deal to develop cancer and fibrotic-disease therapies with Pharmakea Therapeutics Inc., which at the same time pulled down $10 million in a Series A funding round from Bay City Capital.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription